LLY - Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off.
2024-07-13 06:31:00 ET
Eli Lilly (NYSE: LLY) received some great news from regulators last week: Its Alzheimer's treatment obtained the green light from the Food and Drug Administration (FDA).
The new drug, Kisunla, has the potential to be a blockbuster for the company and generate billions in revenue. But despite the recent approval, Eli Lilly's stock isn't skyrocketing.
Normally, when a healthcare stock receives positive news surrounding a much-anticipated treatment, there's some surge in the share price. In Lilly's case, that just hasn't happened. It even briefly declined following the news. Why isn't the stock taking off?
For further details see:
Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off.